We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker FR+CTC Explored for Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 30 Dec 2021
Print article
Image: A colored scanning electron micrograph (SEM) of a breast cancer cell (Photo courtesy of Case Western Reserve University School)
Image: A colored scanning electron micrograph (SEM) of a breast cancer cell (Photo courtesy of Case Western Reserve University School)
The prognosis of breast cancer is dramatically improved owing to progress on the early diagnosis and effective therapy, and the survivor number is higher than any other types of cancers. However, the number of new breast cancer cases reached 2.26 million in 2020, accounted for 11.7% of all new tumor cases.

Folate receptor (FR) is a glycosylated phosphatidylinositol-coupled protein with high affinity and endocytosis and transport capacity for its natural ligand folic acid. It is a cell surface protein that has been proven to be an ideal tumor marker for non-small cell lung cancer. The clinical significance of folate receptor-positive circulating tumor cells (FR+CTC) has been explored.

Clinical Laboratorians at the Renmin Hospital of Wuhan University (Wuhan, China) enrolled in a study 60 breast cancer female patients with a mean age of 52 years (range, 27–75 years) and 32 healthy controls with an age of 52 (range, 40–66 years), from January 2019 to January 2021. The diagnosis for the patients was confirmed by cytology or histopathology. Peripheral blood was collected for isolation of circulating tumor cells (CTC) on the diagnosis in all patients of the cohort. The 27 patients underwent radical mastectomy, and the peripheral blood was also collected in two weeks after the operation.

Circulating tumor cells was isolated with folate receptor-positive (FR+) CTC isolation method using CytoploRare kit (GenoSaber Biotech Co., Ltd., Shanghai, China). The method includes negative enrichment of FR+ circulating tumor cells with immunomagnetic beads to deplete leukocytes first, then CTC level was quantitated by ligand-targeted PCR. First, leukocytes and mononuclear macrophages were removed by anti-CD45 and anti-CD14 magnetic beads. Then, the cells were activated and washed to free up the folate binding site. The carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and cancer antigen 153 (CA153) were measured by chemiluminescent immunoassay.

The investigators reported that the levels of FR+CTC were significantly higher in breast cancer patients compared with healthy controls. The levels of FR+CTC in breast cancer patients and healthy people were 10.95 (7.28–14.15) FU/3 mL and 6.93 (5.46–8.19) FU/3 mL, respectively. The detection rate of FR+CTC was decreased in 19 of 27 patients underwent the surgery in two weeks post-operation compared with pre-operation; statistical analysis showed the difference was significant. They also found that the combination of FR+CTC, CEA, CA125, and CA153 can significantly improve the diagnostic efficiency for breast cancer.

The authors concluded that the detection of FR+CTCs in peripheral blood is simple, noninvasive methods with high sensitivity and specificity. It can be used as a potential biomarker for auxiliary diagnosis and early detection in breast cancer patients. The study was published on December 17, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Renmin Hospital of Wuhan University
GenoSaber Biotech Co., Ltd.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.